ライフサイエンスコーパス: chondrosarcoma

1 the expression of cancer/testis antigens in chondrosarcoma.

2 loci may be required for the development of chondrosarcoma.

3 , and one somatic mutation in a patient with chondrosarcoma.

4 ily located at 9q22-31, in a skeletal myxoid chondrosarcoma.

5 been observed in the myxoid variant of human chondrosarcoma.

6 lecules shown to be involved in conventional chondrosarcoma.

7 osarcoma and one (20%) of five patients with chondrosarcoma.

8 ome of the increased VEGF expression seen in chondrosarcoma.

9 the regulation of VEGF by HDAC4 and Runx2 in chondrosarcoma.

10 y are causes of increased VEGF expression in chondrosarcoma.

11 including osteoarthritis, osteosarcoma, and chondrosarcoma.

12 used as markers of prognostic importance in chondrosarcoma.

13 eutic potential in the future for subsets of chondrosarcoma.

14 oncogene, as a frequent change in high-grade chondrosarcoma.

15 tified in samples of enchondroma and grade 1 chondrosarcoma.

16 xostoses undergo malignant transformation to chondrosarcomas.

17 cases, these exostoses progress to malignant chondrosarcomas.

18 ibed in multiple tumors and more recently in chondrosarcomas.

19 are, together constituting 10% to 15% of all chondrosarcomas.

20 ns in IDH1 or IDH2 in nearly half of central chondrosarcomas.

21 2 cm or greater strongly indicated secondary chondrosarcomas.

22 for differentiation of osteochondromas from chondrosarcomas.

23 linical findings in conventional and variant chondrosarcomas.

24 (15%), G3 (20%), and dedifferentiated (21%) chondrosarcomas.

25 ic findings, except for extraskeletal myxoid chondrosarcomas.

26 anges are diagnostic of extraskeletal myxoid chondrosarcomas.

27 ard to isocitrate dehydrogenase mutations in chondrosarcoma, a disease in which currently available s

28 Using a human chondrosarcoma and a murine osteoblast cell line, hepara

29 This peptide adheres to and kills cells from chondrosarcoma and cervical and breast cancer cell lines

30 own that VEGF is overexpressed in high grade chondrosarcoma and chondrosarcoma cell lines.

31 tments may soon be routine for patients with chondrosarcoma and chordoma for whom surgery alone is in

32 on remains the cornerstone of management for chondrosarcoma and chordoma.

33 inoma, adenoid cystic carcinoma, meningioma, chondrosarcoma and fibromyxoid sarcoma.

34 Two patients with progressive chondrosarcoma and melanoma had stable disease lasting a

35 Loss of heterozygosity (LOH) analysis of chondrosarcomas and chondroblastomas revealed multiple L

36 rentiated, 23 clear cell, and 23 mesenchymal chondrosarcomas and performed immunohistochemistry to st

37 ns (eg, cemento-ossifying fibroma and myxoid chondrosarcoma) and the association of established trans

38 Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multip

39 rphic rhabdomyosarcoma, one dedifferentiated chondrosarcoma, and one malignant peripheral nerve sheat

40 including osteosarcomas, rhabdomyosarcomas, chondrosarcomas, and liposarcomas.

41 gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of

42 As in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bc

43 Chondrosarcomas are a group of tumors that fall into thi

44 Chondrosarcomas are a heterogeneous group of bone and so

45 ed genome-wide CpG methylation sequencing of chondrosarcoma biopsies and found that IDH mutations wer

46 ), grade 3 (80%), and dedifferentiated (29%) chondrosarcomas, but was not found in any samples of enc

47 sive genomic analyses of 49 individuals with chondrosarcoma (cases).

48 n the pericellular matrix of transfected rat chondrosarcoma cell and primary human chondrocytes.

49 bp segment with recombinant Sox9 or with rat chondrosarcoma cell extracts, confirming the binding of

50 2 expression and its potential role in human chondrosarcoma cell invasion and metastasis have yet to

51 P-12 or MMP-12 overexpression can potentiate chondrosarcoma cell invasion in vitro and the lung colon

52 l therapeutic strategies that interfere with chondrosarcoma cell invasion may be identified.

53 pursued this possibility using the Swarm rat chondrosarcoma cell line (RCS-LTC) found to express high

54 inity IL-1R sites were identified in a human chondrosarcoma cell line by means of 125I-IL-1beta bindi

55 n of recombinant CRYBP1 in a transfected rat chondrosarcoma cell line inhibited Col2a1 enhancer activ

56 solated human articular chondrocytes and the chondrosarcoma cell line SW-1353 were activated with pol

57 resulted in reduced promoter activity in the chondrosarcoma cell line SW1353 as shown by CpG-free luc

58 Sox9 associates with CBP/p300 in the chondrosarcoma cell line SW1353 via its carboxyl termini

59 red chondrocytes, a stable long-term culture chondrosarcoma cell line, as well as Chinese hamster ova

60 The Swarm rat chondrosarcoma cell line, RCS-LTC, deposits an extracell

61 SW-1353 cells, a human chondrosarcoma cell line, were stimulated with IL-1beta,

62 of the NT2 expression vector in RSC cells, a chondrosarcoma cell line.

63 sed to compare gene expression between human chondrosarcoma cell lines and normal cartilage.

64 CH1 was not up-regulated or overexpressed in chondrosarcoma cell lines exposed to inflammatory stimul

65 -3 mimetic ABT-737 rendered dedifferentiated chondrosarcoma cell lines sensitive to doxorubicin or ci

66 Chondrosarcoma cell lines were used to test for potentia

67 erexpressed in high grade chondrosarcoma and chondrosarcoma cell lines.

68 F repressed COMP gene expression in both rat chondrosarcoma cells and bone morphogenetic protein-2-tr

69 nase 1 (MMP-1) in articular chondrocytes and chondrosarcoma cells and found that IL-1 induction of MM

70 In this study, transient transfection of rat chondrosarcoma cells and NIH-3T3 fibroblasts demonstrate

71 MT1-MMP messenger RNA (mRNA) is expressed in chondrosarcoma cells and OA chondrocytes.

72 pression of c/EBPbeta, SOX9, and p300 in rat chondrosarcoma cells and primary human articular chondro

73 ly complete loss of the enhancer activity in chondrosarcoma cells and transgenic mice.

74 HrP also increased Col2a1 mRNA levels in rat chondrosarcoma cells as well as 10T1/2 mesenchymal cells

75 ncreased promoter activity of Col11a2 in rat chondrosarcoma cells but not in either BalB/3T3 cells or

76 IGF-2-, VEGF-B- or VEGF-D-stimulated chondrosarcoma cells display markedly higher migratory a

77 the activation of the RhoA pathway in SW1353 chondrosarcoma cells increased SOX9(Ser181) phosphorylat

78 Addition of TIMP-3 to HTB94 human chondrosarcoma cells increased the release of sLRP-1 fra

79 We show that reduced expression of HDAC4 in chondrosarcoma cells increases expression of Runx2 leadi

80 BM40 signal peptide in HEK-293 cells and rat chondrosarcoma cells revealed that the BM40 signal pepti

81 Human chondrosarcoma cells stimulated with inflammatory cytoki

82 Human SW1353 chondrosarcoma cells were transfected with constructs co

83 Rat chondrosarcoma cells were transiently transfected with c

84 an articular chondrocytes (HACs) and SW-1353 chondrosarcoma cells were treated with cytokines and TSA

85 SW-1353 human chondrosarcoma cells were used to study the effects of L

86 In chondrosarcoma cells, MMP-1 induction depends on p38 and

87 In transfected human chondrosarcoma cells, this process is not autoproteolyti

88 ded extracellular network in cultures of rat chondrosarcoma cells.

89 displayed a reduced rate of uptake by HTB94 chondrosarcoma cells.

90 MMP-12) expression and its activity in human chondrosarcoma cells.

91 tein response and cell death pathways in rat chondrosarcoma cells.

92 and biochemical analyses of FGF-treated rat chondrosarcoma chondrocytes, we show that FGF inhibits c

93 Erk activity in FGF2-treated RCS (rat chondrosarcoma) chondrocytes or human primary chondrocyt

94 on and FGF-induced growth arrest of RCS (rat chondrosarcoma) chondrocytes.

95 Chondrosarcoma (CS) is a rare cancer, but it is the seco

96 The pathogenesis of myxoid chondrosarcoma (CS) is poorly understood.

97 ow-grade glioma, cholangiocarcinoma (CC) and chondrosarcoma (CS).

98 One sporadic chondrosarcoma demonstrated LOH for EXT1 and EXT3, while

99 ll line, RCS-LTC (derived from the Swarm rat chondrosarcoma), deposits a copious extracellular matrix

100 Primary bone tumors, osteosarcomas and chondrosarcomas, derive from mesenchymal stem cells comm

101 A proportion of extraskeletal myxoid chondrosarcomas (EMC) have been shown to have a characte

102 tionable; and late recurrences of clear cell chondrosarcomas emphasize the need for long-term follow

103 More than 50% of patients with chondrosarcomas exhibit gain-of-function mutations in ei

104 Two patients with chondrosarcoma experienced durable partial responses to

105 lts of 15 frozen tumor samples of high-grade chondrosarcoma for chromosome 8 are presented.

106 erein that, in contrast to osteosarcomas and chondrosarcomas, for which OSM was cytostatic, OSM induc

107 ents; mean age, 23.4 years) and 34 secondary chondrosarcomas (from 27 male patients and seven female

108 demographic data, histologic diagnosis, and chondrosarcoma grade were recorded.

109 -grade gliomas, acute myeloid leukaemia, and chondrosarcomas, has been the identification of early-oc

110 med in rat chondrosarcoma (RCS) cells, human chondrosarcoma (HTB) cells, and NIH/3T3 cells showed tha

111 s of c-fos oncogene-induced osteosarcoma and chondrosarcoma in addition to c-Fos-inducible systems in

112 ongly expressed in joint cartilage, we found chondrosarcoma in the knee joint and remarkable defects

113 Chondrosarcoma is a heterogeneous collection of malignan

114 Chondrosarcoma is a primary bone tumor with a dismal pro

115 s have established that extraskeletal myxoid chondrosarcoma is a unique entity defined by the presenc

116 The histopathologic variability of chondrosarcomas is reflected in the complexity and lack

117 ukemia, intrahepatic cholangiocarcinoma, and chondrosarcomas, led to intense discovery efforts to del

118 CSAGE and TRAG-3 are expressed in chondrosarcoma, melanoma, and cartilage and testis, but

119 re osteosarcoma (n = 20), lymphoma (n = 18), chondrosarcoma (n = 16), and giant cell tumor (n = 16).

120 y HIF-1alpha, immunohistochemical studies of chondrosarcoma nodules were conducted and revealed that

121 In skeletal (central) chondrosarcomas of varying histopathologic types, the cy

122 By multivariate analysis, grade of chondrosarcoma (P = .026) was the only factor to reach s

123 eukemia (AML), melanoma, thyroid cancer, and chondrosarcoma patients.

124 igated such a role for ADAMTS-3 in Swarm rat chondrosarcoma RCS-LTC cells, which fail to process the

125 bits chondrocyte proliferation both in a rat chondrosarcoma (RCS) cell line and in primary murine cho

126 dramatically inhibited proliferation of rat chondrosarcoma (RCS) cells and arrested their cell cycle

127 oter activity in transiently transfected rat chondrosarcoma (RCS) cells and mouse primary chondrocyte

128 sient-transfection analyses performed in rat chondrosarcoma (RCS) cells, human chondrosarcoma (HTB) c

129 K1/2 or the p38 MAPK pathways applied to rat chondrosarcoma (RCS) chondrocytes significantly prevente

130 benefit of chemotherapy for dedifferentiated chondrosarcomas remains questionable; and late recurrenc

131 In chondrosarcoma research, abnormalities in hereditary mul

132 l lung, thyroid, and ovarian carcinomas, and chondrosarcoma, respectively.

133 tation is the first of its kind described in chondrosarcoma, serving as an identifying marker of chon

134 apoptosis-inducing ligand (Apo2L/TRAIL) for chondrosarcoma, small molecule inhibitor crizotinib for

135 esenchymal, clear cell, and dedifferentiated chondrosarcoma subtypes are extremely rare, together con

136 h p-SMAD2 and PAI-1 was highly active in all chondrosarcoma subtypes, which suggests that TGFbeta inh

137 s as a possible therapeutic strategy in rare chondrosarcoma subtypes.

138 alignancies is an uncommon but real risk for chondrosarcoma survivors; the benefit of chemotherapy fo

139 In human embryonic kidney 293 and chondrosarcoma SW 1353 cells, recombinant pro-CNP was co

140 r distinguishing benign osteochondromas from chondrosarcomas, the sensitivities and specificities wer

141 The prognosis of chondrosarcomas traditionally correlates with histologic

142 g role for targeting Bcl-2 family members in chondrosarcoma treatment, irrespective of the subtype.

143 A third chondrosarcoma underwent LOH for EXT1 and chromosome 3q.